312 related articles for article (PubMed ID: 22316604)
1. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
[TBL] [Abstract][Full Text] [Related]
3. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.
Pandita A; Aldape KD; Zadeh G; Guha A; James CD
Genes Chromosomes Cancer; 2004 Jan; 39(1):29-36. PubMed ID: 14603439
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
[TBL] [Abstract][Full Text] [Related]
6. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
7. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
[TBL] [Abstract][Full Text] [Related]
8. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme.
Liu KJ; Chen CT; Hu WS; Hung YM; Hsu CY; Chuang BF; Juang SH
Int J Oncol; 2004 Mar; 24(3):581-90. PubMed ID: 14767543
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
Bigner SH; Humphrey PA; Wong AJ; Vogelstein B; Mark J; Friedman HS; Bigner DD
Cancer Res; 1990 Dec; 50(24):8017-22. PubMed ID: 2253244
[TBL] [Abstract][Full Text] [Related]
10. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043
[TBL] [Abstract][Full Text] [Related]
11. EGF-effects in vitro and in vivo on a carcinoma cell line rich in EGFR.
Torp SH; Helseth E; Unsgaard G; Dalen A
Anticancer Res; 1995; 15(3):667-70. PubMed ID: 7645940
[TBL] [Abstract][Full Text] [Related]
12. The MET oncogene is a functional marker of a glioblastoma stem cell subtype.
De Bacco F; Casanova E; Medico E; Pellegatta S; Orzan F; Albano R; Luraghi P; Reato G; D'Ambrosio A; Porrati P; Patanè M; Maderna E; Pollo B; Comoglio PM; Finocchiaro G; Boccaccio C
Cancer Res; 2012 Sep; 72(17):4537-50. PubMed ID: 22738909
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
14. Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors.
Minke JM; Schuuring E; van den Berghe R; Stolwijk JA; Boonstra J; Cornelisse C; Hilkens J; Misdorp W
Cancer Res; 1991 Aug; 51(15):4028-37. PubMed ID: 1649697
[TBL] [Abstract][Full Text] [Related]
15. Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.
William D; Mokri P; Lamp N; Linnebacher M; Classen CF; Erbersdobler A; Schneider B
PLoS One; 2017; 12(9):e0185208. PubMed ID: 28934307
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
17. The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.
Theys J; Jutten B; Dubois L; Rouschop KM; Chiu RK; Li Y; Paesmans K; Lambin P; Lammering G; Wouters BG
Radiother Oncol; 2009 Sep; 92(3):399-404. PubMed ID: 19616331
[TBL] [Abstract][Full Text] [Related]
18. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
[TBL] [Abstract][Full Text] [Related]
19. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
20. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target.
Schulte A; Günther HS; Phillips HS; Kemming D; Martens T; Kharbanda S; Soriano RH; Modrusan Z; Zapf S; Westphal M; Lamszus K
Glia; 2011 Apr; 59(4):590-602. PubMed ID: 21294158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
